There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zynerba Pharmaceuticals (NASDAQ: ZYNE) and Agios Pharma (NASDAQ: AGIO) with bullish sentiments.
Zynerba Pharmaceuticals (NASDAQ: ZYNE)
“We view ZYNE’s cannabinoid pipeline as attractive and reiterate our BUY.”
According to TipRanks.com, Lee is a 1-star analyst with an average return of -3.0% and a 43.5% success rate. Lee covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Inc., Actinium Pharmaceuticals, and Asterias Biotherapeutics.
Zynerba Pharmaceuticals has an analyst consensus of Strong Buy.
Agios Pharma (NASDAQ: AGIO)
“Agios halted development of back up PKR activator AG-519 after receiving a clinical.”
According to TipRanks.com, Schmidt is a 5-star analyst with an average return of 17.6% and a 49.2% success rate. Schmidt covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals Inc, Merrimack Pharmaceuticals, and Threshold Pharmaceuticals.
Currently, the analyst consensus on Agios Pharma is Moderate Buy and the average price target is $58.50, representing a 26.3% upside.
In a report issued on December 5, Canaccord Genuity also reiterated a Buy rating on the stock with a $90 price target.